Novel insights into double-stranded RNA-mediated immunopathology.

Weber, F., Wagner, V., Rasmussen, S. B., Hartmann, R. & Paludan, S. R. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. 80, 5059–5064 (2006).

pubmed: 16641297 pmcid: 1472073 doi: 10.1128/JVI.80.10.5059-5064.2006

Son, K. N., Liang, Z. & Lipton, H. L. Double-stranded RNA is detected by immunofluorescence analysis in RNA and DNA virus infections, including those by negative-stranded RNA viruses. J. Virol. 89, 9383–9392 (2015).

pubmed: 26136565 pmcid: 4542381 doi: 10.1128/JVI.01299-15

Hur, S. Double-stranded RNA sensors and modulators in innate immunity. Annu. Rev. Immunol. 37, 349–375 (2019).

pubmed: 30673536 pmcid: 7136661 doi: 10.1146/annurev-immunol-042718-041356

Rice, G. I. et al. Mutations in ADAR1 cause Aicardi–Goutières syndrome associated with a type I interferon signature. Nat. Genet. 44, 1243–1248 (2012). This study provides clinical evidence that the detection of self-dsRNA by the innate immune system may be causal to human immunopathology.

pubmed: 23001123 pmcid: 4154508 doi: 10.1038/ng.2414

Chen, Y. G. & Hur, S. Cellular origins of dsRNA, their recognition and consequences. Nat. Rev. Mol. Cell Biol. 23, 286–301 (2022).

pubmed: 34815573 doi: 10.1038/s41580-021-00430-1

Bartok, E. & Hartmann, G. Immune sensing mechanisms that discriminate self from altered self and foreign nucleic acids. Immunity 53, 54–77 (2020).

pubmed: 32668228 pmcid: 7359798 doi: 10.1016/j.immuni.2020.06.014

Aicardi, J. & Goutieres, F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann. Neurol. 15, 49–54 (1984).

pubmed: 6712192 doi: 10.1002/ana.410150109

Crow, Y. J. & Stetson, D. B. The type I interferonopathies: 10 years on. Nat. Rev. Immunol. 22, 471–483 (2022).

pubmed: 34671122 doi: 10.1038/s41577-021-00633-9

Livingston, J. H. et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J. Med. Genet. 51, 76–82 (2014).

pubmed: 24262145 doi: 10.1136/jmedgenet-2013-102038

Crow, Y. J. et al. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics 45, 386–393 (2014).

pubmed: 25243380 doi: 10.1055/s-0034-1389161

La Piana, R. et al. Bilateral striatal necrosis in two subjects with Aicardi–Goutières syndrome due to mutations in ADAR1 (AGS6). Am. J. Med. Genet. A 164A, 815–819 (2014).

pubmed: 24376015 doi: 10.1002/ajmg.a.36360

Rice, G. I. et al. Genetic, phenotypic, and interferon biomarker status in ADAR1-related neurological disease. Neuropediatrics 48, 166–184 (2017).

pubmed: 28561207 pmcid: 5985975 doi: 10.1055/s-0037-1601449

Miyamura, Y. et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am. J. Hum. Genet. 73, 693–699 (2003).

pubmed: 12916015 pmcid: 1180697 doi: 10.1086/378209

Hayashi, M. & Suzuki, T. Dyschromatosis symmetrica hereditaria. J. Dermatol. 40, 336–343 (2013).

pubmed: 22974014 doi: 10.1111/j.1346-8138.2012.01661.x

Nishikura, K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat. Rev. Mol. Cell Biol. 17, 83–96 (2016).

pubmed: 26648264 doi: 10.1038/nrm.2015.4

Walkley, C. R. & Li, J. B. Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs. Genome Biol. 18, 205 (2017).

pubmed: 29084589 pmcid: 5663115 doi: 10.1186/s13059-017-1347-3

Gallo, A., Vukic, D., Michalik, D., O’Connell, M. A. & Keegan, L. P. ADAR RNA editing in human disease; more to it than meets the I. Hum. Genet. 136, 1265–1278 (2017).

pubmed: 28913566 doi: 10.1007/s00439-017-1837-0

Eisenberg, E. & Levanon, E. Y. A-to-I RNA editing—immune protector and transcriptome diversifier. Nat. Rev. Genet. 19, 473–490 (2018).

pubmed: 29692414 doi: 10.1038/s41576-018-0006-1

Jain, M., Jantsch, M. F. & Licht, K. The editor’s I on disease development. Trends Genet 35, 903–913 (2019).

pubmed: 31648814 doi: 10.1016/j.tig.2019.09.004

Samuel, C. E. Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses. J. Biol. Chem. 294, 1710–1720 (2019).

pubmed: 30710018 pmcid: 6364763 doi: 10.1074/jbc.TM118.004166

Bass, B. L. & Weintraub, H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 55, 1089–1098 (1988).

pubmed: 3203381 doi: 10.1016/0092-8674(88)90253-X

Wagner, R. W., Smith, J. E., Cooperman, B. S. & Nishikura, K. A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs. Proc. Natl Acad. Sci. USA 86, 2647–2651 (1989).

pubmed: 2704740 pmcid: 286974 doi: 10.1073/pnas.86.8.2647

George, C. X. & Samuel, C. E. Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. Proc. Natl Acad. Sci. USA 96, 4621–4626 (1999).

pubmed: 10200312 pmcid: 16382 doi: 10.1073/pnas.96.8.4621

Kawakubo, K. & Samuel, C. E. Human RNA-specific adenosine deaminase (ADAR1) gene specifies transcripts that initiate from a constitutively active alternative promoter. Gene 258, 165–172 (2000).

pubmed: 11111054 doi: 10.1016/S0378-1119(00)00368-1

George, C. X., Wagner, M. V. & Samuel, C. E. Expression of interferon-inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissue-selective promoter utilization and alternative splicing. J. Biol. Chem. 280, 15020–15028 (2005).

pubmed: 15677478 doi: 10.1074/jbc.M500476200

Sun, T. et al. Decoupling expression and editing preferences of ADAR1 p150 and p110 isoforms. Proc. Natl Acad. Sci. USA 118, e2021757118 (2021).

pubmed: 33723056 pmcid: 8000508 doi: 10.1073/pnas.2021757118

Liang, Z., Goradia, A., Walkley, C. R. & Heraud-Farlow, J. E. Generation of a new Adar1p150

pubmed: 37290963 doi: 10.1261/rna.079509.122

Tian, B., Bevilacqua, P. C., Diegelman-Parente, A. & Mathews, M. B. The double-stranded-RNA-binding motif: interference and much more. Nat. Rev. Mol. Cell Biol. 5, 1013–1023 (2004).

pubmed: 15573138 doi: 10.1038/nrm1528

Gleghorn, M. L. & Maquat, L. E. ‘Black sheep’ that don’t leave the double-stranded RNA-binding domain fold. Trends Biochem. Sci. 39, 328–340 (2014).

pubmed: 24954387 pmcid: 4077987 doi: 10.1016/j.tibs.2014.05.003

Poulsen, H., Nilsson, J., Damgaard, C. K., Egebjerg, J. & Kjems, J. CRM1 mediates the export of ADAR1 through a nuclear export signal within the Z-DNA binding domain. Mol. Cell. Biol. 21, 7862–7871 (2001).

pubmed: 11604520 pmcid: 99958 doi: 10.1128/MCB.21.22.7862-7871.2001

Strehblow, A., Hallegger, M. & Jantsch, M. F. Nucleocytoplasmic distribution of human RNA-editing enzyme ADAR1 is modulated by double-stranded RNA-binding domains, a leucine-rich export signal, and a putative dimerization domain. Mol. Biol. Cell 13, 3822–3835 (2002).

pubmed: 12429827 pmcid: 133595 doi: 10.1091/mbc.e02-03-0161

Patterson, J. B. & Samuel, C. E. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol. Cell. Biol. 15, 5376–5388 (1995).

pubmed: 7565688 pmcid: 230787 doi: 10.1128/MCB.15.10.5376

Slavov, D., Crnogorac-Jurcevic, T., Clark, M. & Gardiner, K. Comparative analysis of the DRADA A-to-I RNA editing gene from mammals, pufferfish and zebrafish. Gene 250, 53–60 (2000).

pubmed: 10854778 doi: 10.1016/S0378-1119(00)00175-X

Kim, Y. G. et al. A role for Z-DNA binding in vaccinia virus pathogenesis. Proc. Natl Acad. Sci. USA 100, 6974–6979 (2003).

pubmed: 12777633 pmcid: 165815 doi: 10.1073/pnas.0431131100

Athanasiadis, A. et al. The crystal structure of the Zβ domain of the RNA-editing enzyme ADAR1 reveals distinct conserved surfaces among Z-domains. J. Mol. Biol. 351, 496–507 (2005).

pubmed: 16023667 doi: 10.1016/j.jmb.2005.06.028

Inoue, M. et al. An Aicardi–Goutières syndrome-causative point mutation in Adar1 gene invokes multiorgan inflammation and late-onset encephalopathy in mice. J. Immunol. 207, 3016–3027 (2021).

pubmed: 34772697 doi: 10.4049/jimmunol.2100526

Guo, X. et al. Aicardi–Goutières syndrome-associated mutation at ADAR1 gene locus activates innate immune response in mouse brain. J. Neuroinflammation 18, 169 (2021).

pubmed: 34332594 pmcid: 8325854 doi: 10.1186/s12974-021-02217-9

Guo, X. et al. An AGS-associated mutation in ADAR1 catalytic domain results in early-onset and MDA5-dependent encephalopathy with IFN pathway activation in the brain. J. Neuroinflammation 19, 285 (2022).

pubmed: 36457126 pmcid: 9714073 doi: 10.1186/s12974-022-02646-0

Matthews, M. M. et al. Structures of human ADAR2 bound to dsRNA reveal base-flipping mechanism and basis for site selectivity. Nat. Struct. Mol. Biol. 23, 426–433 (2016).

pubmed: 27065196 pmcid: 4918759 doi: 10.1038/nsmb.3203

Fisher, A. J. & Beal, P. A. Effects of Aicardi–Goutières syndrome mutations predicted from ADAR–RNA structures. RNA Biol. 14, 164–170 (2017).

pubmed: 27937139 doi: 10.1080/15476286.2016.1267097

Cho, D. S. et al. Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J. Biol. Chem. 278, 17093–17102 (2003).

pubmed: 12618436 doi: 10.1074/jbc.M213127200

Valente, L. & Nishikura, K. RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions. J. Biol. Chem. 282, 16054–16061 (2007).

pubmed: 17428802 doi: 10.1074/jbc.M611392200

Mannion, N. M. et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 9, 1482–1494 (2014). This study shows that the MAVS signalling pathway causes the embryonic lethality of Adar-knockout mice.

pubmed: 25456137 pmcid: 4542304 doi: 10.1016/j.celrep.2014.10.041

Wang, Q. et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J. Biol. Chem. 279, 4952–4961 (2004).

pubmed: 14613934 doi: 10.1074/jbc.M310162200

Hartner, J. C. et al. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J. Biol. Chem. 279, 4894–4902 (2004). Together with Wang et al. (2004), this study describes the original (conditional) Adar-knockout mouse models, which have been extensively used in genetic studies.

pubmed: 14615479 doi: 10.1074/jbc.M311347200

Levanon, E. Y. et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol. 22, 1001–1005 (2004).

pubmed: 15258596 doi: 10.1038/nbt996

Athanasiadis, A., Rich, A. & Maas, S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2, e391 (2004).

pubmed: 15534692 pmcid: 526178 doi: 10.1371/journal.pbio.0020391

Kim, D. D. et al. Widespread RNA editing of embedded Alu elements in the human transcriptome. Genome Res. 14, 1719–1725 (2004).

pubmed: 15342557 pmcid: 515317 doi: 10.1101/gr.2855504

Blow, M., Futreal, P. A., Wooster, R. & Stratton, M. R. A survey of RNA editing in human brain. Genome Res. 14, 2379–2387 (2004).

pubmed: 15545495 pmcid: 534661 doi: 10.1101/gr.2951204

Bazak, L., Levanon, E. Y. & Eisenberg, E. Genome-wide analysis of Alu editability. Nucleic Acids Res. 42, 6876–6884 (2014).

pubmed: 24829451 pmcid: 4066801 doi: 10.1093/nar/gku414

Zhang, X. O., Pratt, H. & Weng, Z. Investigating the potential roles of SINEs in the human genome. Annu. Rev. Genomics Hum. Genet. 22, 199–218 (2021).

pubmed: 33792357 doi: 10.1146/annurev-genom-111620-100736

Bahn, J. H. et al. Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways. Nat. Commun. 6, 6355 (2015).

pubmed: 25751603 doi: 10.1038/ncomms7355

Neeman, Y., Levanon, E. Y., Jantsch, M. F. & Eisenberg, E. RNA editing level in the mouse is determined by the genomic repeat repertoire. RNA 12, 1802–1809 (2006).

pubmed: 16940548 pmcid: 1581974 doi: 10.1261/rna.165106

Licht, K. et al. A high resolution A-to-I editing map in the mouse identifies editing events controlled by pre-mRNA splicing. Genome Res. 29, 1453–1463 (2019).

pubmed: 31427386 pmcid: 6724681 doi: 10.1101/gr.242636.118

Porath, H. T., Knisbacher, B. A., Eisenberg, E. & Levanon, E. Y. Massive A-to-I RNA editing is common across the Metazoa and correlates with dsRNA abundance. Genome Biol. 18, 185 (2017).

pubmed: 28969707 pmcid: 5625713 doi: 10.1186/s13059-017-1315-y

Bazak, L. et al. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 24, 365–376 (2014).

pubmed: 24347612 pmcid: 3941102 doi: 10.1101/gr.164749.113

Song, Y. et al. irCLASH reveals RNA substrates recognized by human ADARs. Nat. Struct. Mol. Biol. 27, 351–362 (2020).

pubmed: 32203492 doi: 10.1038/s41594-020-0398-4

Solomon, O. et al. RNA editing by ADAR1 leads to context-dependent transcriptome-wide changes in RNA secondary structure. Nat. Commun. 8, 1440 (2017).

pubmed: 29129909 pmcid: 5682290 doi: 10.1038/s41467-017-01458-8

Uzonyi, A. et al. Deciphering the principles of the RNA editing code via large-scale systematic probing. Mol. Cell 81, 2374–2387.e3 (2021).

pubmed: 33905683 doi: 10.1016/j.molcel.2021.03.024

Scadden, A. D. & O’Connell, M. A. Cleavage of dsRNAs hyper-edited by ADARs occurs at preferred editing sites. Nucleic Acids Res. 33, 5954–5964 (2005).

pubmed: 16254076 pmcid: 1270950 doi: 10.1093/nar/gki909

Scadden, A. D. The RISC subunit Tudor-SN binds to hyper-edited double-stranded RNA and promotes its cleavage. Nat. Struct. Mol. Biol. 12, 489–496 (2005).

pubmed: 15895094 doi: 10.1038/nsmb936

Morita, Y. et al. Human endonuclease V is a ribonuclease specific for inosine-containing RNA. Nat. Commun. 4, 2273 (2013).

pubmed: 23912718 doi: 10.1038/ncomms3273

Vitali, P. & Scadden, A. D. Double-stranded RNAs containing multiple IU pairs are sufficient to suppress interferon induction and apoptosis. Nat. Struct. Mol. Biol. 17, 1043–1050 (2010).

pubmed: 20694008 pmcid: 2935675 doi: 10.1038/nsmb.1864

Hartner, J. C., Walkley, C. R., Lu, J. & Orkin, S. H. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat. Immunol. 10, 109–115 (2009). This study shows that ADAR1 functions as a negative regulator of type I interferon signalling.

pubmed: 19060901 doi: 10.1038/ni.1680

Pestal, K. et al. Isoforms of RNA-editing enzyme adar1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development. Immunity 43, 933–944 (2015). This study shows that ADAR1-p150 prevents MDA5-mediated immunopathology.

pubmed: 26588779 pmcid: 4654992 doi: 10.1016/j.immuni.2015.11.001

Heraud-Farlow, J. E. et al. Protein recoding by ADAR1-mediated RNA editing is not essential for normal development and homeostasis. Genome Biol. 18, 166 (2017).

pubmed: 28874170 pmcid: 5585977 doi: 10.1186/s13059-017-1301-4

Berke, I. C. & Modis, Y. MDA5 cooperatively forms dimers and ATP-sensitive filaments upon binding double-stranded RNA. EMBO J. 31, 1714–1726 (2012).

pubmed: 22314235 pmcid: 3321199 doi: 10.1038/emboj.2012.19

Peisley, A. et al. Kinetic mechanism for viral dsRNA length discrimination by MDA5 filaments. Proc. Natl Acad. Sci. USA 109, E3340–E3349 (2012).

pubmed: 23129641 pmcid: 3523859 doi: 10.1073/pnas.1208618109

Hou, F. et al. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146, 448–461 (2011).

pubmed: 21782231 pmcid: 3179916 doi: 10.1016/j.cell.2011.06.041

Liu, S. et al. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. eLife 2, e00785 (2013).

pubmed: 23951545 pmcid: 3743401 doi: 10.7554/eLife.00785

Fang, R. et al. MAVS activates TBK1 and IKKε through TRAFs in NEMO dependent and independent manner. PLoS Pathog. 13, e1006720 (2017).

pubmed: 29125880 pmcid: 5699845 doi: 10.1371/journal.ppat.1006720

Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat. Rev. Immunol. 20, 537–551 (2020).

pubmed: 32203325 pmcid: 7094958 doi: 10.1038/s41577-020-0288-3

Lei, Y. et al. MAVS-mediated apoptosis and its inhibition by viral proteins. PLoS ONE 4, e5466 (2009).

pubmed: 19404494 pmcid: 2674933 doi: 10.1371/journal.pone.0005466

Huang, Y. et al. MAVS–MKK7–JNK2 defines a novel apoptotic signaling pathway during viral infection. PLoS Pathog. 10, e1004020 (2014).

pubmed: 24651600 pmcid: 3961361 doi: 10.1371/journal.ppat.1004020

El Maadidi, S. et al. A novel mitochondrial MAVS/caspase-8 platform links RNA virus-induced innate antiviral signaling to Bax/Bak-independent apoptosis. J. Immunol. 192, 1171–1183 (2014).

pubmed: 24391214 doi: 10.4049/jimmunol.1300842

Liddicoat, B. J. et al. Adenosine-to-inosine RNA editing by ADAR1 is essential for normal murine erythropoiesis. Exp. Hematol. 44, 947–963 (2016).

pubmed: 27373493 pmcid: 5035604 doi: 10.1016/j.exphem.2016.06.250

Lazear, H. M., Schoggins, J. W. & Diamond, M. S. Shared and distinct functions of type I and type III interferons. Immunity 50, 907–923 (2019).

pubmed: 30995506 pmcid: 6839410 doi: 10.1016/j.immuni.2019.03.025

Philips, R. L. et al. The JAK–STAT pathway at 30: much learned, much more to do. Cell 185, 3857–3876 (2022).

pubmed: 36240739 pmcid: 9815833 doi: 10.1016/j.cell.2022.09.023

Ourthiague, D. R. et al. Limited specificity of IRF3 and ISGF3 in the transcriptional innate-immune response to double-stranded RNA. J. Leukoc. Biol. 98, 119–128 (2015).

pubmed: 25896227 pmcid: 4467169 doi: 10.1189/jlb.4A1014-483RR

Bajad, P. et al. An internal deletion of ADAR rescued by MAVS deficiency leads to a minute phenotype. Nucleic Acids Res. 48, 3286–3303 (2020).

pubmed: 31956894 pmcid: 7102943 doi: 10.1093/nar/gkaa025

Garcia-Gonzalez, C. et al. ADAR1 prevents autoinflammatory processes in the heart mediated by IRF7. Circ. Res. 131, 580–597 (2022).

pubmed: 36000401 doi: 10.1161/CIRCRESAHA.122.320839

Honda, K. et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772–777 (2005).

pubmed: 15800576 doi: 10.1038/nature03464

Maurano, M. et al. Protein kinase R and the integrated stress response drive immunopathology caused by mutations in the RNA deaminase ADAR1. Immunity 54, 1948–1960.e5 (2021). This study provides in vivo evidence that PKR activation contributes to the immunopathology of mice with hemizygous Zα domain P195A-mutant ADAR1 expression.

pubmed: 34343497 pmcid: 8446335 doi: 10.1016/j.immuni.2021.07.001

Liddicoat, B. J. et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 349, 1115–1120 (2015). This study reports the generation of an ADAR1 editing-deficient knock-in mouse, showing that A-to-I editing is crucial to prevent spontaneous MDA5 activation.

pubmed: 26275108 pmcid: 5444807 doi: 10.1126/science.aac7049

Goodman, R. A., Macbeth, M. R. & Beal, P. A. ADAR proteins: structure and catalytic mechanism. Curr. Top. Microbiol. Immunol. 353, 1–33 (2012).

pubmed: 21769729

Lai, F., Drakas, R. & Nishikura, K. Mutagenic analysis of double-stranded RNA adenosine deaminase, a candidate enzyme for RNA editing of glutamate-gated ion channel transcripts. J. Biol. Chem. 270, 17098–17105 (1995).

pubmed: 7615504 doi: 10.1074/jbc.270.29.17098

Ahmad, S. et al. Breaching self-tolerance to alu duplex RNA underlies MDA5-mediated inflammation. Cell 172, 797–810.e13 (2018).

pubmed: 29395326 pmcid: 5807104 doi: 10.1016/j.cell.2017.12.016

Barak, M. et al. Purifying selection of long dsRNA is the first line of defense against false activation of innate immunity. Genome Biol. 21, 26 (2020).

pubmed: 32028986 pmcid: 7006430 doi: 10.1186/s13059-020-1937-3

Rice, G. I. et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat. Genet. 46, 503–509 (2014).

pubmed: 24686847 pmcid: 4004585 doi: 10.1038/ng.2933

Oda, H. et al. Aicardi–Goutières syndrome is caused by IFIH1 mutations. Am. J. Hum. Genet. 95, 121–125 (2014).

pubmed: 24995871 pmcid: 4085581 doi: 10.1016/j.ajhg.2014.06.007

Li, Q. et al. RNA editing underlies genetic risk of common inflammatory diseases. Nature 608, 569–577 (2022).

pubmed: 35922514 pmcid: 9790998 doi: 10.1038/s41586-022-05052-x

Chen, J., Sun, M., Hurst, L. D., Carmichael, G. G. & Rowley, J. D. Genome-wide analysis of coordinate expression and evolution of human cis-encoded sense–antisense transcripts. Trends Genet. 21, 326–329 (2005).

pubmed: 15922830 doi: 10.1016/j.tig.2005.04.006

Kato, H. et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205, 1601–1610 (2008).

pubmed: 18591409 pmcid: 2442638 doi: 10.1084/jem.20080091

Bruns, A. M., Leser, G. P., Lamb, R. A. & Horvath, C. M. The innate immune sensor LGP2 activates antiviral signaling by regulating MDA5–RNA interaction and filament assembly. Mol. Cell 55, 771–781 (2014).

pubmed: 25127512 pmcid: 4156907 doi: 10.1016/j.molcel.2014.07.003

Stok, J. E. et al. RNA sensing via the RIG-I-like receptor LGP2 is essential for the induction of a type I IFN response in ADAR1 deficiency. EMBO J. 41, e109760 (2022).

pubmed: 35156720 pmcid: 8922249 doi: 10.15252/embj.2021109760

Schmelzer, L. et al. Variable clinical phenotype in two siblings with Aicardi–Goutières syndrome type 6 and a novel mutation in the ADAR gene. Eur. J. Paediatr. Neurol. 22, 186–189 (2018).

pubmed: 29221912 doi: 10.1016/j.ejpn.2017.11.003

Wang, W. et al. Analysis of clinical characteristics of children with Aicardi–Goutières syndrome in China. World J. Pediatr. 18, 490–497 (2022).

pubmed: 35551623 pmcid: 9205831 doi: 10.1007/s12519-022-00545-1

Ward, S. V. et al. RNA editing enzyme adenosine deaminase is a restriction factor for controlling measles virus replication that also is required for embryogenesis. Proc. Natl Acad. Sci. USA 108, 331–336 (2011). This study reports the generation of Adar-p150-specific knockout mice, which phenocopy the embryonic lethality of full Adar-knockout mice.

pubmed: 21173229 doi: 10.1073/pnas.1017241108

Hu, S.-B. et al. ADAR1p150 prevents MDA5 and PKR activation via distinct mechanisms to avert fatal autoinflammation. Preprint at bioRxiv https://doi.org/10.1101/2023.01.25.525475 (2023).

Kim, J. I. et al. RNA editing at a limited number of sites is sufficient to prevent MDA5 activation in the mouse brain. PLoS Genet. 17, e1009516 (2021). This study reports the generation of Adar-p110-specific knockout mice, which in contrast to p150-knockout mice do not develop MDA5-mediated embryonic lethality.

pubmed: 33983932 pmcid: 8118328 doi: 10.1371/journal.pgen.1009516

Barraud, P., Banerjee, S., Mohamed, W. I., Jantsch, M. F. & Allain, F. H. A bimodular nuclear localization signal assembled via an extended double-stranded RNA-binding domain acts as an RNA-sensing signal for transportin 1. Proc. Natl Acad. Sci. USA 111, E1852–E1861 (2014).

pubmed: 24753571 pmcid: 4020056 doi: 10.1073/pnas.1323698111

Eckmann, C. R., Neunteufl, A., Pfaffstetter, L. & Jantsch, M. F. The human but not the Xenopus RNA-editing enzyme ADAR1 has an atypical nuclear localization signal and displays the characteristics of a shuttling protein. Mol. Biol. Cell 12, 1911–1924 (2001).

pubmed: 11451992 pmcid: 55639 doi: 10.1091/mbc.12.7.1911

Kleinova, R. et al. The ADAR1 editome reveals drivers of editing-specificity for ADAR1-isoforms. Nucleic Acids Res. 51, 4191–4207 (2023).

pubmed: 37026479 pmcid: 10201426 doi: 10.1093/nar/gkad265

Sun, T. et al. A small subset of cytosolic dsRNAs must be edited by ADAR1 to evade MDA5-mediated autoimmunity. Preprint at bioRxiv https://doi.org/10.1101/2022.08.29.505707 (2022).

Yang, J. H. et al. Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation. Immunology 109, 15–23 (2003).

pubmed: 12709013 pmcid: 1782949 doi: 10.1046/j.1365-2567.2003.01598.x

George, C. X., Ramaswami, G., Li, J. B. & Samuel, C. E. Editing of cellular self-RNAs by adenosine deaminase ADAR1 suppresses innate immune stress responses. J. Biol. Chem. 291, 6158–6168 (2016).

pubmed: 26817845 pmcid: 4813567 doi: 10.1074/jbc.M115.709014

Chung, H. et al. Human ADAR1 prevents endogenous RNA from triggering translational shutdown. Cell 172, 811–824.e14 (2018).

pubmed: 29395325 pmcid: 5831367 doi: 10.1016/j.cell.2017.12.038

Zhang, T. et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature 606, 594–602 (2022).

pubmed: 35614224 pmcid: 9373927 doi: 10.1038/s41586-022-04753-7

Krall, J. B., Nichols, P. J., Henen, M. A., Vicens, Q. & Vogeli, B. Structure and formation of Z-DNA and Z-RNA. Molecules 28, 843 (2023).

pubmed: 36677900 pmcid: 9867160 doi: 10.3390/molecules28020843

Nichols, P. J., Krall, J. B., Henen, M. A., Vogeli, B. & Vicens, Q. Z-RNA biology: a central role in the innate immune response? RNA 29, 273–281 (2023).

pubmed: 36596670 pmcid: 9945438 doi: 10.1261/rna.079429.122

Sathishkumar, D. et al. Co-occurrence of Aicardi–Goutières syndrome type 6 and dyschromatosis symmetrica hereditaria due to compound heterozygous pathogenic variants in ADAR1: a case series from India. Clin. Exp. Dermatol. 46, 704–709 (2021).

pubmed: 33289110 doi: 10.1111/ced.14531

Schwartz, T., Rould, M. A., Lowenhaupt, K., Herbert, A. & Rich, A. Crystal structure of the Zα domain of the human editing enzyme ADAR1 bound to left-handed Z-DNA. Science 284, 1841–1845 (1999).

pubmed: 10364558 doi: 10.1126/science.284.5421.1841

Placido, D., Brown, B. A. 2nd, Lowenhaupt, K., Rich, A. & Athanasiadis, A. A left-handed RNA double helix bound by the Zα domain of the RNA-editing enzyme ADAR1. Structure 15, 395–404 (2007).

pubmed: 17437712 pmcid: 2082211 doi: 10.1016/j.str.2007.03.001

Schade, M., Turner, C. J., Lowenhaupt, K., Rich, A. & Herbert, A. Structure-function analysis of the Z-DNA-binding domain Zα of dsRNA adenosine deaminase type I reveals similarity to the (α + β) family of helix–turn–helix proteins. EMBO J. 18, 470–479 (1999).

pubmed: 9889202 pmcid: 1171140 doi: 10.1093/emboj/18.2.470

de Reuver, R. et al. ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation. Cell Rep. 36, 109500 (2021).

pubmed: 34380029 doi: 10.1016/j.celrep.2021.109500

Tang, Q. et al. Adenosine-to-inosine editing of endogenous Z-form RNA by the deaminase ADAR1 prevents spontaneous MAVS-dependent type I interferon responses. Immunity 54, 1961–1975 e1965 (2021).

pubmed: 34525337 pmcid: 8459395 doi: 10.1016/j.immuni.2021.08.011

Nakahama, T. et al. Mutations in the adenosine deaminase ADAR1 that prevent endogenous Z-RNA binding induce Aicardi–Goutières-syndrome-like encephalopathy. Immunity 54, 1976–1988.e7 (2021).

pubmed: 34525338 doi: 10.1016/j.immuni.2021.08.022

Jiao, H. et al. ADAR1 averts fatal type I interferon induction by ZBP1. Nature 607, 776–783 (2022).

pubmed: 35859176 pmcid: 9329096 doi: 10.1038/s41586-022-04878-9

Liang, Z. et al. The phenotype of the most common human ADAR1p150 Zα mutation P193A in mice is partially penetrant. EMBO Rep. 24, e55835 (2023).

pubmed: 36975179 doi: 10.15252/embr.202255835

Guo, X. et al. ADAR1 Zα domain P195A mutation activates the MDA5-dependent RNA-sensing signaling pathway in brain without decreasing overall RNA editing. Cell Rep. 42, 112733 (2023). Together with Maurano et al. (2021), de Reuver et al. (2021), Tang et al. (2021), Nakahama et al. (2021), Jiao et al. (2022) and Liang et al. (EMBO Rep., 2023), this work shows that Zα domain mutation of ADAR1 causes spontaneous MDA5 activation.

pubmed: 37421629 doi: 10.1016/j.celrep.2023.112733

Feng, S. et al. Alternate rRNA secondary structures as regulators of translation. Nat. Struct. Mol. Biol. 18, 169–176 (2011).

pubmed: 21217697 doi: 10.1038/nsmb.1962

de Reuver, R. et al. ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation. Nature 607, 784–789 (2022).

pubmed: 35859175 doi: 10.1038/s41586-022-04974-w

Koeris, M., Funke, L., Shrestha, J., Rich, A. & Maas, S. Modulation of ADAR1 editing activity by Z-RNA in vitro. Nucleic Acids Res. 33, 5362–5370 (2005).

pubmed: 16177183 pmcid: 1226316 doi: 10.1093/nar/gki849

Nichols, P. J. et al. Recognition of non-CpG repeats in Alu and ribosomal RNAs by the Z-RNA binding domain of ADAR1 induces A-Z junctions. Nat. Commun. 12, 793 (2021).

pubmed: 33542240 pmcid: 7862695 doi: 10.1038/s41467-021-21039-0

Nie, Y., Hammond, G. L. & Yang, J. H. Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus infection. J. Virol. 81, 917–923 (2007).

pubmed: 17079286 doi: 10.1128/JVI.01527-06

Costa-Mattioli, M. & Walter, P. The integrated stress response: from mechanism to disease. Science 368, eaat5314 (2020).

pubmed: 32327570 pmcid: 8997189 doi: 10.1126/science.aat5314

Hubbard, N. W. et al. ADAR1 mutation causes ZBP1-dependent immunopathology. Nature 607, 769–775 (2022).

pubmed: 35859177 pmcid: 9339495 doi: 10.1038/s41586-022-04896-7

Kaiser, W. J., Upton, J. W. & Mocarski, E. S. Receptor-interacting protein homotypic interaction motif-dependent control of NF-κB activation via the DNA-dependent activator of IFN regulatory factors. J. Immunol. 181, 6427–6434 (2008).

pubmed: 18941233 doi: 10.4049/jimmunol.181.9.6427

Rebsamen, M. et al. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-κB. EMBO Rep. 10, 916–922 (2009).

pubmed: 19590578 pmcid: 2726668 doi: 10.1038/embor.2009.109

Peng, R. et al. Human ZBP1 induces cell death-independent inflammatory signaling via RIPK3 and RIPK1. EMBO Rep. 23, e55839 (2022).

pubmed: 36268590 pmcid: 9724671 doi: 10.15252/embr.202255839

Thapa, R. J. et al. DAI senses influenza A virus genomic RNA and activates RIPK3-dependent cell death. Cell Host Microbe 20, 674–681 (2016).

pubmed: 27746097 pmcid: 5687825 doi: 10.1016/j.chom.2016.09.014

Kuriakose, T. et al. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci. Immunol. 1, aag2045 (2016).

pubmed: 27917412 pmcid: 5131924 doi: 10.1126/sciimmunol.aag2045

Upton, J. W., Kaiser, W. J. & Mocarski, E. S. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 11, 290–297 (2012).

pubmed: 22423968 pmcid: 3531981 doi: 10.1016/j.chom.2012.01.016

Lei, X., Chen, Y., Lien, E. & Fitzgerald, K. A. MLKL-driven inflammasome activation and caspase-8 mediate inflammatory cell death in influenza a virus infection. mBio 14, e0011023 (2023).

pubmed: 36852999 doi: 10.1128/mbio.00110-23

Zheng, M., Karki, R., Vogel, P. & Kanneganti, T. D. Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense. Cell 181, 674–687.e13 (2020).

pubmed: 32298652 pmcid: 7425208 doi: 10.1016/j.cell.2020.03.040

Karki, R. et al. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis. Cell Rep. 37, 109858 (2021). Together with Zhang et al. (2022), Jiao et al. (2022), de Reuver et al. (2022) and Hubbard et al. (2022), this work identifies ADAR1 as a negative regulator of ZBP1 activation.

pubmed: 34686350 pmcid: 8853634 doi: 10.1016/j.celrep.2021.109858

Kreuz, S., Siegmund, D., Scheurich, P. & Wajant, H. NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21, 3964–3973 (2001).

pubmed: 11359904 pmcid: 87059 doi: 10.1128/MCB.21.12.3964-3973.2001

Nassour, J. et al. Telomere-to-mitochondria signalling by ZBP1 mediates replicative crisis. Nature 614, 767–773 (2023).

pubmed: 36755096 pmcid: 9946831 doi: 10.1038/s41586-023-05710-8

Lei, Y. et al. Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity. Cell 186, 3013–3032.e22 (2023).

pubmed: 37352855 doi: 10.1016/j.cell.2023.05.039

Li, Y. et al. Ribonuclease L mediates the cell-lethal phenotype of double-stranded RNA editing enzyme ADAR1 deficiency in a human cell line. eLife 6, e25687 (2017).

pubmed: 28362255 pmcid: 5404912 doi: 10.7554/eLife.25687

Peisley, A., Wu, B., Yao, H., Walz, T. & Hur, S. RIG-I forms signaling-competent filaments in an ATP-dependent, ubiquitin-independent manner. Mol. Cell 51, 573–583 (2013).

pubmed: 23993742 doi: 10.1016/j.molcel.2013.07.024

Patel, J. R. et al. ATPase-driven oligomerization of RIG-I on RNA allows optimal activation of type-I interferon. EMBO Rep. 14, 780–787 (2013).

pubmed: 23846310 pmcid: 3790048 doi: 10.1038/embor.2013.102

Hornung, V. et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314, 994–997 (2006).

pubmed: 17038590 doi: 10.1126/science.1132505

Goubau, D. et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates. Nature 514, 372–375 (2014).

pubmed: 25119032 pmcid: 4201573 doi: 10.1038/nature13590

Pichlmair, A. et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314, 997–1001 (2006).

pubmed: 17038589 doi: 10.1126/science.1132998

Peisley, A. et al. Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. Proc. Natl Acad. Sci. USA 108, 21010–21015 (2011).

pubmed: 22160685 pmcid: 3248507 doi: 10.1073/pnas.1113651108

Uchikawa, E. et al. Structural analysis of dsRNA binding to anti-viral pattern recognition receptors LGP2 and MDA5. Mol. Cell 62, 586–602 (2016).

pubmed: 27203181 pmcid: 4885022 doi: 10.1016/j.molcel.2016.04.021

Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732–738 (2001).

pubmed: 11607032 doi: 10.1038/35099560

Lind, N. A., Rael, V. E., Pestal, K., Liu, B. & Barton, G. M. Regulation of the nucleic acid-sensing Toll-like receptors. Nat. Rev. Immunol. 22, 224–235 (2022).

pubmed: 34272507 doi: 10.1038/s41577-021-00577-0

Sadler, A. J. & Williams, B. R. Structure and function of the protein kinase R. Curr. Top. Microbiol. Immunol. 316, 253–292 (2007).

pubmed: 17969452

Donnelly, N., Gorman, A. M., Gupta, S. & Samali, A. The eIF2α kinases: their structures and functions. Cell. Mol. Life Sci. 70, 3493–3511 (2013).

pubmed: 23354059 doi: 10.1007/s00018-012-1252-6

Hornung, V., Hartmann, R., Ablasser, A. & Hopfner, K. P. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat. Rev. Immunol. 14, 521–528 (2014).

pubmed: 25033909 pmcid: 7097587 doi: 10.1038/nri3719

Karki, R. & Kanneganti, T. D. ADAR1 and ZBP1 in innate immunity, cell death, and disease. Trends Immunol. 44, 201–216 (2023).

pubmed: 36710220 doi: 10.1016/j.it.2023.01.001

Maelfait, J. & Rehwinkel, J. The Z-nucleic acid sensor ZBP1 in health and disease. J. Exp. Med. 220, e20221156 (2023).

pubmed: 37450010 pmcid: 10347765 doi: 10.1084/jem.20221156

DeAntoneo, C., Herbert, A. & Balachandran, S. Z-Form nucleic acid-binding protein 1 (ZBP1) as a sensor of viral and cellular Z-RNAs: walking the razor’s edge. Curr. Opin. Immunol. 83, 102347 (2023).

pubmed: 37276820 doi: 10.1016/j.coi.2023.102347

Bauernfried, S., Scherr, M. J., Pichlmair, A., Duderstadt, K. E. & Hornung, V. Human NLRP1 is a sensor for double-stranded RNA. Science 371, eabd0811 (2021).

pubmed: 33243852 doi: 10.1126/science.abd0811

Wang, P. et al. Nlrp6 regulates intestinal antiviral innate immunity. Science 350, 826–830 (2015).

pubmed: 26494172 pmcid: 4927078 doi: 10.1126/science.aab3145

Shen, C. et al. Phase separation drives RNA virus-induced activation of the NLRP6 inflammasome. Cell 184, 5759–5774.e20 (2021).

pubmed: 34678144 pmcid: 8643277 doi: 10.1016/j.cell.2021.09.032

Hong, X. X. & Carmichael, G. G. Innate immunity in pluripotent human cells: attenuated response to interferon-β. J. Biol. Chem. 288, 16196–16205 (2013).

pubmed: 23599426 pmcid: 3668775 doi: 10.1074/jbc.M112.435461

Poirier, E. Z. et al. An isoform of Dicer protects mammalian stem cells against multiple RNA viruses. Science 373, 231–236 (2021).

pubmed: 34244417 pmcid: 7611482 doi: 10.1126/science.abg2264

Kim, U., Wang, Y., Sanford, T., Zeng, Y. & Nishikura, K. Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc. Natl Acad. Sci. USA 91, 11457–11461 (1994).

pubmed: 7972084 pmcid: 45250 doi: 10.1073/pnas.91.24.11457

Melcher, T. et al. A mammalian RNA editing enzyme. Nature 379, 460–464 (1996).

pubmed: 8559253 doi: 10.1038/379460a0

Chen, C. X. et al. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 6, 755–767 (2000).

pubmed: 10836796 pmcid: 1369955 doi: 10.1017/S1355838200000170

Tan, M. H. et al. Dynamic landscape and regulation of RNA editing in mammals. Nature 550, 249–254 (2017).

pubmed: 29022589 pmcid: 5723435 doi: 10.1038/nature24041

Oakes, E., Anderson, A., Cohen-Gadol, A. & Hundley, H. A. Adenosine deaminase that acts on RNA 3 (ADAR3) binding to glutamate receptor subunit B pre-mRNA inhibits RNA editing in glioblastoma. J. Biol. Chem. 292, 4326–4335 (2017).

pubmed: 28167531 pmcid: 5354488 doi: 10.1074/jbc.M117.779868

Raghava Kurup, R. et al. RNA binding by ADAR3 inhibits adenosine-to-inosine editing and promotes expression of immune response protein MAVS. J. Biol. Chem. 298, 102267 (2022).

pubmed: 35850307 pmcid: 9418441 doi: 10.1016/j.jbc.2022.102267

Sommer, B., Kohler, M., Sprengel, R. & Seeburg, P. H. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 67, 11–19 (1991).

pubmed: 1717158 doi: 10.1016/0092-8674(91)90568-J

Higuchi, M. et al. RNA editing of AMPA receptor subunit GluR-B: a base-paired intron–exon structure determines position and efficiency. Cell 75, 1361–1370 (1993).

pubmed: 8269514 doi: 10.1016/0092-8674(93)90622-W

Greger, I. H., Watson, J. F. & Cull-Candy, S. G. Structural and functional architecture of AMPA-type glutamate receptors and their auxiliary proteins. Neuron 94, 713–730 (2017).

pubmed: 28521126 doi: 10.1016/j.neuron.2017.04.009

Barbon, A., Vallini, I., La Via, L., Marchina, E. & Barlati, S. Glutamate receptor RNA editing: a molecular analysis of GluR2, GluR5 and GluR6 in human brain tissues and in NT2 cells following in vitro neural differentiation. Brain Res. Mol. Brain Res. 117, 168–178 (2003).

pubmed: 14559151 doi: 10.1016/S0169-328X(03)00317-6

Burnashev, N., Monyer, H., Seeburg, P. H. & Sakmann, B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron 8, 189–198 (1992).

pubmed: 1370372 doi: 10.1016/0896-6273(92)90120-3

Higuchi, M. et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 406, 78–81 (2000).

pubmed: 10894545 doi: 10.1038/35017558

Gajiwala, K. S. & Burley, S. K. Winged helix proteins. Curr. Opin. Struct. Biol. 10, 110–116 (2000).

pubmed: 10679470 doi: 10.1016/S0959-440X(99)00057-3

Herbert, A. et al. A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. Proc. Natl Acad. Sci. USA 94, 8421–8426 (1997).

pubmed: 9237992 pmcid: 22942 doi: 10.1073/pnas.94.16.8421

Schwartz, T., Behlke, J., Lowenhaupt, K., Heinemann, U. & Rich, A. Structure of the DLM-1–Z-DNA complex reveals a conserved family of Z-DNA-binding proteins. Nat. Struct. Biol. 8, 761–765 (2001).

pubmed: 11524677 doi: 10.1038/nsb0901-761

Rothenburg, S. et al. A PKR-like eukaryotic initiation factor 2α kinase from zebrafish contains Z-DNA binding domains instead of dsRNA binding domains. Proc. Natl Acad. Sci. USA 102, 1602–1607 (2005).

pubmed: 15659550 pmcid: 547857 doi: 10.1073/pnas.0408714102

Nikpour, N. & Salavati, R. The RNA binding activity of the first identified trypanosome protein with Z-DNA-binding domains. Sci. Rep. 9, 5904 (2019).

pubmed: 30976048 pmcid: 6459835 doi: 10.1038/s41598-019-42409-1

Tome, A. R. et al. Crystal structure of a poxvirus-like Zα domain from cyprinid herpesvirus 3. J. Virol. 87, 3998–4004 (2013).

pubmed: 23365431 pmcid: 3624203 doi: 10.1128/JVI.03116-12

Rich, A., Nordheim, A. & Wang, A. H. The chemistry and biology of left-handed Z-DNA. Annu. Rev. Biochem. 53, 791–846 (1984).

pubmed: 6383204 doi: 10.1146/annurev.bi.53.070184.004043

Klysik, J., Stirdivant, S. M., Singleton, C. K., Zacharias, W. & Wells, R. D. Effects of 5 cytosine methylation on the B–Z transition in DNA restriction fragments and recombinant plasmids. J. Mol. Biol. 168, 51–71 (1983).

pubmed: 6308270 doi: 10.1016/S0022-2836(83)80322-2

Novel insights into double-stranded RNA-mediated immunopathology.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Richard de Reuver (R)

Jonathan Maelfait (J)

Classifications MeSH